More that one million patients
each year enter end-stage congestive heart failure.
With only an estimated 3,500 transplants performed
annually, the VentrAssist™ device is designed
as a permanent alternative to heart transplant therapy.
VentrAssistŪLVAD
Ventracor's core business is the rapid commercialisation of the VentrAssistŪLVAD.
Clinical trials to collect supporting data for CE Mark approval and permission to sell in the major market of Europe are now underway.
